Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Domain Therapeutics
Biotech
Ovid eyes next chapter with CEO transition—Chutes & Ladders
Ovid's Levin set to become chairman as its next CEO stands ready. FDA’s oncology head takes top CDER post. Metagenomi shuffles CEO in reorg. Plus more.
Darren Incorvaia
,
Zoey Becker
Nov 14, 2025 8:30am
MHRA CEO Raine to depart in Autumn —Chutes & Ladders
Mar 1, 2024 9:30am
Boehringer inks pact with Domain for GPCR neurology drugs
Dec 4, 2018 9:30am
Merck KGaA pens pact, eyes checkpoint inhibitor combos
Jan 23, 2017 9:19am
Medicxi founds Parkinson’s startup, commits €9M
Oct 18, 2016 9:05am
